Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Generate Biomedicines states that its AI-enabled...read more
The 2026 IPO market started the year on reasonably steady footing as nine listings raised a combined $2.6 billion in January. Despite a mounting backlog of startups indicating IPO plans this year, many initially stayed on the sidelines and let others test...read more
Apeiron Acquisition Vehicle I, a blank check company targeting cross-border and international operations, announced terms for its IPO on Wednesday. The New York, NY-based company plans to raise $70 million by offering 7 million units at a price of $10. Each...read more
Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Generate Biomedicines states that its AI-enabled...read more
Renaissance Capital's January IPO Market Update
The 2026 IPO market started the year on reasonably steady footing as nine listings raised a combined $2.6 billion in January. Despite a mounting backlog of startups indicating IPO plans this year, many initially stayed on the sidelines and let others test...read more
SPAC Apeiron Acquisition files for $70 million IPO, targeting international operations
Apeiron Acquisition Vehicle I, a blank check company targeting cross-border and international operations, announced terms for its IPO on Wednesday. The New York, NY-based company plans to raise $70 million by offering 7 million units at a price of $10. Each...read more